Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy

Circulation

Volumn 119, Issue 18, 2009, Pages 2480-2489

  Wang, Xiang ^a   Chow, Fung Lan ^a   Oka, Tatsujiro ^a   Hao, Li ^a   Lopez Campistrous, Ana ^a   Kelly, Sandra ^a   Cooper, Stephan ^a   Odenbach, Jeffrey ^a   Finegan, Barry A ^a   Schulz, Richard ^a   Kassiri, Zamaneh ^a   Lopaschuk, Gary D ^a   Fernandez Patron, Carlos ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Gene therapy; Hypertension; Hypertrophy; Metalloproteinases; Remodeling; Vasculature

Indexed keywords

ADAM PROTEIN; ANGIOTENSIN II; ANTISENSE OLIGONUCLEOTIDE; DOXYCYCLINE; GELATINASE A; MATRILYSIN; N(G) NITROARGININE METHYL ESTER; NORADRENALIN; PHENYLEPHRINE; PROTEIN ADAM 12; UNCLASSIFIED DRUG; ADAM12 PROTEIN, MOUSE; ADAM12 PROTEIN, RAT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION REGULATION; ZYMOGRAPHY; ACUTE DISEASE; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; WISTAR KYOTO RAT;

ACUTE DISEASE; ADAM PROTEINS; ADRENERGIC ALPHA-AGONISTS; ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HYPERTENSION; MATRIX METALLOPROTEINASE 7; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; NOREPINEPHRINE; PHENYLEPHRINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 66549083058     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.835488     Document Type: Article

References (28)

1. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556.
2. Biaggioni I. Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension. 2008;51: 168-171.
3. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors? Can J Physiol Pharmacol. 2007; 85:97-104.
4. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402:884-888.
5. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM 12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35-40.
6. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasocon-striction through the epidermal growth factor-receptor pathway. Circ Res. 2004;94:68-76.
7. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2006;26: e133-e137.
8. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579.
9. Okamoto T, Akuta T, Tamura F, van Der Vliet A, Akaike T. Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation. Biol Chem. 2004;385:997-1006.
10. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van-Bilsen M, O'Brien TX, Evans SM. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol. 1993;55:77-95.
11. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005;11:867-874.
12. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000;105:143-150.
13. Sunnarborg SW, Hinkle CL, Stevenson M, Russell WE, Raska CS, Peschon JJ, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Lee DC. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem. 2002;277: 12838-12845.
14. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metallopro-teinase matrilysin. Proc Natl Acad Sci U S A. 1997;94:1402-1407.
15. Momiyama N, Koshikawa N, Ishikawa T, Ichikawa Y, Hasegawa S, Nagashima Y, Mitsuhashi M, Miyazaki K, Shimada H. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro. Mol Carcinog. 1998;22:57-63.
16. Yonemura Y, Endo Y, Fujita H, Kimura K, Sugiyama K, Momiyama N, Shimada H, Sasaki T. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J Exp Clin Cancer Res. 2001;20:205-212.
17. Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ishikawa T, Mitsuhashi M, Shimada H, Miyazaki K. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer. 1998;76:812-816.
18. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990;101:746-752.
19. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophys-iology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
20. Lauhio A, Konttinen YT, Salo T, Tschesche H, Nordstrom D, Lahdevirta J, Golub LM, Sorsa T. The in vivo effect of doxycycline treatment on matrix metalloproteinases in reactive arthritis. Ann N Y Acad Sci. 1994; 732:431-432.
21. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, Hultgren SJ, Matrisian LM, Parks WC. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999;286:113-117.
22. Zhang YC, Bui JD, Shen L, Phillips MI. Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation. 2000;101:682-688.
23. Nava E, Noll G, Luscher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation. 1995;91:2310-2313.
24. Kawasaki H, Cline WH Jr, Su C. Involvement of the vascular renin-angiotensin system in beta adrenergic receptor-mediated facilitation of vascular neurotransmission in spontaneously hypertensive rats. J Pharmacol Exp Ther. 1984;231:23-32.
25. Wang FQ, So J, Reierstad S, Fishman DA. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005;114:19-31.
26. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matrisian LM, Spinale FG. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006;113:2919-2928.
27. Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, Verma S, Weisel RD, Li RK. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation. 2006;113:238-245.
28. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoan-tibodies induce preeclampsia in pregnant mice. Nat Med. 2008;14: 855-862.